Skip to content
Triangle logo TriangleGet started
← Study library

NCT04267575 · REGISTRY CONDITION SEARCH

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
NA
Status at capture
UNKNOWN
Registry last update
2021-08-09

The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection).. Plasma is an ionized gas typically generated in high-temperature laboratory conditions. Plasma coagulators are currently used routinely as surgical tools with multiple applications that create temperatures between 37° C to 43°C and cause thermal injury. Earlier studies demonstrated the non-aggressive nature of cold plasma. As evidence accumulates, it is becoming clear that low-temperature cold plasma has an increasing role in biomedical applications.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Complications Due To Cold Plasma Application

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Solid tumors undergoing surgical treatment with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection). * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study and must be willing to return for follow-up * 18 years of age or older and capable of providing informed consent indicating awareness of the investigational nature of this trial, in keeping with Good Clinical Practice (GCP) guidelines and institutional policy. * Biopsy (histopathology or cytology) diagnosis of a solid tumor as defined by the World Health Organization (WHO) or by cross-sectional imaging reviewed by a board-certified radiologist. * Good performance status (ECOG \< 2), Karnofsky \>60%, * Patients with low or acceptable surgical risk (American society of Anesthesiology (ASA) score of 3 or less. * Patient is a candidate for surgical therapy as discussed and recommended by the institutional disease management team (DMT, Tumor Board). At the time of enrollment: * Absolute neutrophil count (ANC) exceeds 1200/mm3, white blood cell count exceeds 4000/mm3 and platelet count is greater than 100,000/mm3 * An international normalized ratio (INR) ≤ 1.5 (patients who are therapeutically anticoagulated for non-related medical conditions such as atrial fibrillation and whose anti-thrombotic treatment can be withheld for operation will be eligible). * Adequate hepatic function must be met as evidenced by total serum bilirubin ≤ 3.0 mg/dl ; alkaline phosphatase \< 2.5 times the upper limit of normal; and, aspartate aminotransferase (AST) less than 1.5 times upper limit of normal \[alkaline phosphatase and AST cannot both exceed the upper limit of normal\] * Serum renal functional parameters, blood urea nitrogen (BUN) and creatinine are within normal limits * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation. * Life expectancy of at least six months Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Patients with unresectable tumors as decided by a multidisciplinary disease management team * Patients with multiple metastatic sites not amenable for surgical resection * Pregnancy or lactation * Patients with low performance status (ECOG \> 2 or Karnofsky \< 60%) * Any one or more of the following hematological abnormalities * Hgb \< 8gm/dl unable to be corrected with transfusion * Absolute Neutrophil Count \< 1200/mm3 * White blood cell count \< 4000/mm3 * Platelet count \< 100,000/mm3 * INR \> 1.5 (except in patients who are therapeutically AST anticoagulated for non-related medical conditions such as atrial fibrillation and whose anti-thrombotic treatment cannot be withheld for operation will be eligible) * History of hepatic cirrhosis or present hepatic dysfunction * Alkaline phosphatase ≥ 2.5 times the upper limit of normal * ≥ 1.5 times upper limit of normal * Serum bilirubin \> 3.0 mg/dl * Alkaline phosphatase and AST both exceed the upper limit of normal * Renal insufficiency indicated by a serum creatinine \>1.5mg/dL. * Patients with high surgical risk (ASA 4-5) with significant history of a medical problem that would preclude the patient from undergoing an operative procedure such as a history of severe congestive heart failure or active ischemic heart disease. * Febrile illness within 7 days before scheduled surgery * Treatment with another investigational drug or other intervention within 60 days before surgery * Patients that are unable to- or unwilling to provide a written informed consent * Patients who underwent treatment with cold plasma within a year before study entry.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.
    intervention Names
    1. Device: Canady Helios Cold Plasma Scalpel
    label
    Primary Arm
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Primary Arm
    description
    Device used to distribute cold plasma energy at the resected tumor margins.
    name
    Canady Helios Cold Plasma Scalpel
    type
    DEVICE
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
20
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Adverse events (CTCAE event version 4.03 to 5.0) within 30 days after Canady Helios Cold Plasma Scalpel treatment.
    measure
    Number of Participants With Complications Due To Cold Plasma Application
    time Frame
    Immediate after application of cold plasma, followed by 3 months, 6 months, 12 months and 15 month observations.
Full study description
brief Summary
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection).. Plasma is an ionized gas typically generated in high-temperature laboratory conditions. Plasma coagulators are currently used routinely as surgical tools with multiple applications that create temperatures between 37° C to 43°C and cause thermal injury. Earlier studies demonstrated the non-aggressive nature of cold plasma. As evidence accumulates, it is becoming clear that low-temperature cold plasma has an increasing role in biomedical applications.
Source references
references
  1. citation
    Canady J, Murthy SRK, Zhuang T, Gitelis S, Nissan A, Ly L, Jones OZ, Cheng X, Adileh M, Blank AT, Colman MW, Millikan K, O'Donoghue C, Stenson KM, Ohara K, Schtrechman G, Keidar M, Basadonna G. The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer. Cancers (Basel). 2023 Jul 20;15(14):3688. doi: 10.3390/cancers15143688.
    pmid
    37509349
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-24e12d9aca274e6c0cbf
      requested nct id
      NCT04267575
      primary nct id
      NCT04267575
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      payload sha256
      2a4ca4589b557b044726e835010cc8453d95d386be7436eb4261549c7bfe7a60
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-24e12d9aca274e6c0cbf
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT04267575
      occurrences
      1. context exact
        NCT04267575
        end
        11
        exact text
        NCT04267575
        start
        0
      offset unit
      unicode_code_points
      query cond
      Small Intestine Cancer
      query disease state id
      ds-small-intestine-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      source json pointer
      /studies/11/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      09234147489c59706871af997bd1772087bd349ae08e05269cbd6c65956bc2cc
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-c8a261bfbdf5c5f943f4
      requested nct id
      NCT04267575
      primary nct id
      NCT04267575
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      397f70079fd453b2425308e1bcf203d722820e7dd949f962de4cb807de7d65c3
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-c8a261bfbdf5c5f943f4
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT04267575
      occurrences
      1. context exact
        NCT04267575
        end
        11
        exact text
        NCT04267575
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/128/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      09234147489c59706871af997bd1772087bd349ae08e05269cbd6c65956bc2cc

    Preserved source evidence · Not medical advice